SAN DIEGO, May 15 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. , a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it was selected for addition to the NASDAQ Biotechnology Index (NBI), effective as of the market’s opening on May 22, 2006.
“We are pleased to be included in the NASDAQ Biotechnology Index and believe that our selection to this index is further recognition of our consistent progress and achievements,” said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA. “We look forward to continuing to execute on our strategy of building a broad pipeline of innovative therapies to treat central nervous system disorders and other areas of unmet medical need.”
Launched in 1993, the NASDAQ Biotechnology Index includes companies that are listed on the NASDAQ national market and meet minimum requirements, including market value, average daily share volume, and seasoning as a public company, among other criteria. The index is ranked on a semi-annual basis in May and November and serves as the basis for the iShares NASDAQ Biotechnology Index Fund . For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit www.nasdaq.com.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has five Phase II-stage clinical programs as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs, including schizophrenia, Parkinson’s disease, sleep maintenance insomnia, and neuropathic pain. All of the drug candidates in ACADIA’s product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA’s corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmo, Sweden.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to the progress and potential of ACADIA’s programs and business. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, collaborations with others, and litigation. For a discussion of these and other factors, please refer to ACADIA’s annual report on Form 10-K for the year ended December 31, 2005 as well as other subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Contacts: ACADIA Pharmaceuticals Inc. Lisa Barthelemy, Director, Investor Relations Thomas H. Aasen, Vice President and Chief Financial Officer (858) 558-2871
ACADIA Pharmaceuticals Inc.
CONTACT: Lisa Barthelemy, Director, Investor Relations, or Thomas H.Aasen, Vice President and Chief Financial Officer, both of ACADIAPharmaceuticals Inc., +1-858-558-2871
